HER2 Support Group Forums > Breast Cancer Meeting Highlights

Pages : 1 2 3 [4]

751. Characteristics of subsequent breast cancers in patients with benign breast disease (0 replies)
752. registHER: Treatment outcomes in patients with HER2+ hormone+ MBC (0 replies)
753. Peptide Vaccine (0 replies)
754. Immune-Based Lymphoma Treatment Shows Promise (0 replies)
755. Oxidative Stress, Obesity, and Breast Cancer Risk: Results From the Shanghai Women's (0 replies)
756. Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cycl (0 replies)
757. ASCO: Conflicting Data on Breast Cancer, Tamoxifen, SSRIs (0 replies)
758. Small molecule inhibitor shows promise in trastuzumab-resistant metastatic breast can (0 replies)
759. Roche Presents Several Abstracts for New Targeted Cancer Drugs at ASCO (0 replies)
760. Roche's Herceptin Promises New Use (0 replies)
761. Cancer Drugs: News from ASCO (0 replies)
762. ASCO: New Drug Class Promising in Breast Cancer (0 replies)
763. Article from Orlando (0 replies)
764. Cancer stem cells: consensus at ASCO? (0 replies)
765. Data on REOLYSIN® Clinical Trials at ASCO Conference (2 replies)
766. Risk and cost of anthracycline-induced cardiotoxicity among breast cancer patients in (0 replies)
767. Long-term treatment with intravenous bisphosphonates in metastatic breast cancer (0 replies)
768. Complications associated with erythropoietin stimulating agents in mbc patients (0 replies)
769. The role of systemic treatment after whole brain radiotherapy (WBRT) in bc patients (0 replies)
770. Pertuzumab monotherapy following trastuzumab-based treatment (1 replies)
771. Phase II study of trastuzumab-DM1: Final results (0 replies)
772. Off-label drug use in women with breast cancer (0 replies)
773. Surgery vs primary endocrine therapy for elderly women (0 replies)
774. Weight gain after adjuvant TAC (docetaxel, doxorubicin, and cyclophosphamide) chemo (0 replies)
775. Sensitivity to endocrine therapy of PR+/ER- patients and ER+/PR- patients with HER2+ (0 replies)
776. Trastuzumab cardiotoxicity: FDA review (0 replies)
777. Response to neoadjuvant chemotherapy and outcome based on breast cancer subtype (1 replies)
778. Long-term follow-up and factors of survival of HER-2 positive breast cancer patients (0 replies)
779. HER-2/neu in tissue and serum at time of primary diagnosis of breast cancer (0 replies)
780. Risk factors associated with trastuzumab-associated cardiac toxicity (0 replies)
781. Evaluation of Adjuvant! Online to predict the effect of optimal endocrine therapy (0 replies)
782. Association between HER2/neu overexpression and calcifications in breast cancer (0 replies)
783. trial of acupuncture for the management of AI associated joint symptoms (0 replies)
784. trastuzumab-related cardiac dysfunction in the HERA Trial with 3.6 years follow- up (0 replies)
785. Expression profile of CTC and corresponding tumors in primary breast cancer patients (0 replies)
786. PIK3CA gene expression signature and prognosis within the luminal-B ER+ bc (0 replies)
787. Treatment of node-negative infra-centimetric HER2+ invasive breast carcinomas (0 replies)
788. Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen (0 replies)
789. Anthracyclines in Early Breast Cancer: Patient Perspectives and Expert Debate (2 replies)
790. Combined ER and HER-targeted therapy in breast cancer treatment (1 replies)
791. Testosterone protection: Salivary hormone levels in newly diagnosed breast cancer pts (0 replies)
792. Primary endocrine therapy versus chemo in postmen pts w/ ER+ bc: 5 yr results (0 replies)
793. Chronobiological rhythms of cytokines level of breast cancer (0 replies)
794. Radiofrequency ablation of early breast cancer followed by delayed surgical resection (0 replies)
795. Soreness and sensitivity to sun exposure 10 to 16 years after breast cancer radiother (0 replies)
796. Is there a promotion of metastasis by autologeous breast reconstruction in patients? (0 replies)
797. The timing of recurrence after the surgery of breast cancer (0 replies)
798. CYP2D6 pharmacogenetics stratifies tamoxifen treatment outcome (0 replies)
799. Tumor size vs Her2 amplification in post-meno, ER+ tamoxifen tx pts (0 replies)
800. The coamplification pattern of HER2/NEU amplicon and its clinical significance (0 replies)
801. Presence of an in-situ component is associated with reduced biological aggressiveness (0 replies)
802. Breast Cancer Podcasts. (1 replies)
803. Musa Meyer's Blog on SABCS (0 replies)
804. Drinking more green tea after reading this abstract (0 replies)
805. SABC another abstract on her2+ early stage outcomes... (2 replies)
806. San Antonio Abstract on-Significant increased recurrence rates among breast cancer .. (1 replies)
807. Pooled cardiac safety analysis of patients with HER2+ MBC receiving trastuzumab (0 replies)
808. Low penetrance breast cancer predisposition SNPs are site specific (0 replies)
809. HER2 amplification predicts breast cancer recurrence but not overall survival (3 replies)
810. HER2 amplification does not alter outcome in small (1 cm) tumors (0 replies)
811. PR receptor levels are associated with time to AI treatment failure (0 replies)
812. HER-2/neu expression/amplification is not stable during tumor progression (0 replies)
813. Remarkable complete pathologic response rate in Her2+ stage II/III pts in phase II tr (0 replies)
814. The addition of zoledronic acid to neoadjuvant chemotherapy may influence pathologica (0 replies)
815. Promoter hypermethylation is an early event in breast carcinogenesis (0 replies)
816. Is metabolic syndrome the link between obesity and postmenopausal breast cancer? (0 replies)
817. Abundance and distribution of polychlorinated biphenyls (PCBs) in breast tissue (0 replies)
818. Metastatic potential of Her2+ and Her2- CETC released during primary systemic chemo (0 replies)
819. HER2 Support Group Awards 2 Scholarships (1 replies)
820. Behaviour and metastatic potential of Her2+ and Her2-(CETC) during adjuvant therapy (0 replies)
821. HER-2 expression on circulating tumor cells in metastatic breast cancer (0 replies)
822. A novel breast tissue feature strongly associated with risk of breast cancer (0 replies)
823. BCafter stopping estrogen plus progestin in postmenopausal women in the whi (0 replies)
824. Complications of methylene blue dye infiltration for sentinel lymph node biopsy in bc (0 replies)
825. RFA of lumpectomy cavities: technique to increase negative margins (0 replies)
826. San Antonio Breast Cancer Symposium 2008 (2 replies)
827. BC patients unknowingly dosing themselves with estrogen by using topical moisturizers (9 replies)
828. Reliable data on 5- and 10-year survival provides accurate estimates of 15-year survi (0 replies)
829. Tumor necrosis factor transactivates ErbB2 in breast cancer cells (0 replies)
830. Histologic markers of mammographic breast density: core-needle biopsy tissue from (0 replies)
831. Evaluation of aromatase expression in mammographically dense and non-dense regions of (0 replies)
832. Combination antiHER therapeutics efficacy of alternative dosing regimens in ER+/HER2 (0 replies)
833. HER2 positive early breast cancers: tumour demographics and trastuzumab therapy (0 replies)
834. Trastuzumab 6 mg/kg and 4 mg/kg can be infused safely over 30 minutes (0 replies)
835. Trastuzumab treatment in elderly patients with advanced breast cancer (0 replies)
836. Hercetpin tx for recurrence free patients with persistent DTC in bone marrow (0 replies)
837. Study on survival times for stage IV bc over 3 decades (0 replies)
838. electro-acupuncture for aromatase inhibitor related arthralgia in bc survivors (0 replies)
839. Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted (0 replies)
840. Deletion of STAT5 prevents HER2/Neu/ErbB2-induced mammary tumor development (0 replies)
841. Intermittent treatment of hormone-dependent breast cancer using exemestane (0 replies)
842. Lapatinib can activate or supress estrogen receptor (ER) signaling in cell models of (0 replies)
843. Determination of HER2 amplification - when should chromosome 17 also be determined (2 replies)
844. Neratinib (HKI-272), an irreversible pan erbB receptor tyrosine kinase inhibitor (0 replies)
845. MG28, a novel fatty acid synthase inhibitor, overcomes resistance to anti-HER therapy (0 replies)
846. Reduction of chemotherapy side effects with a calcium phosphate nanoparticle delivery (0 replies)
847. Estimating recurrences prevented from using trastuzumab in adjuvant bc in the USA (0 replies)
848. Clinical outcomes of patients with T1N0 breast cancers: how important are biological (0 replies)
849. Influence of zoledronic acid on disseminated tumor cells (DTC) in primary bc (0 replies)
850. The pattern of metastatic spread among breast cancer sub-types (0 replies)
851. Using mathematical models to understand the time dependence of the growth of DCIS (0 replies)
852. HER-2+ DCIS phenotypes and the transition from in situ to invasive breast cancer (0 replies)
853. Decreased TGF signaling and increased COX2 expression in dense breasts (0 replies)
854. Prognostic value of Ki-67 in ER+ grade 2 tumors (0 replies)
855. HER2 homodimer levels correlate w/time to first recurrence in HER2+ bc w/o Herceptin (0 replies)
856. Metastasis-associated microtentacles are induced by Tau (1 replies)
857. survival outcomes in HER2 positive breast cancer patients with low grade, nn tumors (0 replies)
858. Normal breast tissue from bc patients express HER1-4 protein concentrations character (0 replies)
859. The effect of intermittent versus continuous energy restriction on biomarkers of bc (0 replies)
860. A distinct inflammatory marker pattern in patients with AI-induced muculoskeletal sym (0 replies)
861. San Antonio Abstracts on line Early (0 replies)
862. Antivascular activity of lapatinib and bevacizumab in primary microcluster cultures (1 replies)
863. Early stage BC and Zometa trial results (2 replies)
864. Drug enhances several therapies (0 replies)
865. Incidence of Heart Failure from Herceptin does not increase over time (4 replies)
866. HER2/HR status & FEC & paclitaxel (0 replies)
867. HER2 Survival Rates - We've come a long way (0 replies)
868. Avastin shows promise in HER2- breast cancer (2 replies)
869. ASCO 2008 - The Group Room (0 replies)
870. More Advocacy Opportunities at ASCO (0 replies)
871. 2008 ASCO Patient Advocate Scholarships Available (0 replies)
872. Tykerb Targets Cancer Stem Cells (1 replies)
873. Arimidex most effective in breast cancer study (0 replies)
874. Outcome of HER-2-positive breast cancer tied to hormone receptor status (0 replies)
875. US Oncology Research Network Presents Clinical Studies (0 replies)
876. Proteomic Blood Test Detects Breast Cancer in Early Trial (0 replies)
877. Men Can Also Be Carriers Of Breast Cancer Genes (0 replies)
878. Fat-Derived Stem Cells Used for Breast Reconstruction (0 replies)
879. Gene Test Can Indicate Whether Tamoxifen Can Fight Breast Cancer (0 replies)
880. Multiple Studies Reinforce Clinical Utility of Oncotype (0 replies)
881. Brenda's Story Featured! (14 replies)
882. For R.B - Her2 and fatty acid synthase in bc cells (0 replies)
883. Multidisciplinary management of menopause symptoms after breast cancer (0 replies)
884. Confirmatory Tissue Biopsy for BC mets strongly recommended (0 replies)
885. BC patients w/1-3 positive nodes and low risk 70-gene profile have excellent survival (0 replies)
886. Several Articles from San Antonio (0 replies)
887. Brazilian team finds Herceptin cost effective (0 replies)
888. IHC versus FISH (0 replies)
889. Further Development of INCB7839 as a New Oral Treatment for Breast Cancer (2 replies)
890. Importance Of Emotional/educational Needs Among Women With Advanced Breast Cancer (0 replies)
891. Five-Year Cutoff on Tamoxifen Adjuvant Therapy Called Off Base Advice (0 replies)
892. Drug Combination Shrinks Breast Cancer Metastases In Brain (0 replies)
893. Tykerb shows more brain benefits (0 replies)
894. Agent Aims at Restoring Hormone-Sensitive Status of Breast Cancer Tumor Cells (0 replies)
895. New Drug to Prevent Bone Loss Caused by Breast Cancer Treatment (2 replies)
896. HERmark Presents Assay Results In Metastatic Breast Cancer (0 replies)
897. Addition of Xeloda to Herceptin and Docetaxel (0 replies)
898. The TEACH (Tykerb Evaluation After CHemotherapy) trial (0 replies)
899. Herceptin Helps Women With Multiple Chromosomes Containing HER2 Gene, Study Finds (0 replies)
900. Xeloda(R), Taxotere(R) and Herceptin(R) Combination Study Suggests Clinical Benefit i (0 replies)
901. Breast Cancer Patients Benefit From Continued Use of Herceptin After Progression (0 replies)
902. Ten Years of Tamoxifen May Be Better than Five, but Questions Remain (0 replies)
903. Targeting EGFR in Triple-Negative Breast Cancer (0 replies)
904. To Remove or Not to Remove: Scientists Report on Signs That May Guide Lymph Node Deci (0 replies)
905. Roche Says Avastin Safe in Trials With Chemotherapy (Update1) (0 replies)
906. Anastrozole, marketed as Arimidex, produces better results than tamoxifen (0 replies)
907. Stem Cells Used to Fix Breast Defects (0 replies)
908. Aromatase Inhibitor Benefit Continues After End of Treatment (0 replies)
909. High-Dose Chemo Gets Final Nail in Its Coffin (2 replies)
910. Shorter Adjuvant Radiation Course Found Safe and Effective After Lumpectomy (0 replies)
911. Zoledronic Acid Prevents Bone Loss during Endocrine Therapy (0 replies)
912. Docetaxel (Taxotere) Outdoes Doxorubicin (Adriamycin) (0 replies)
913. Benefits of Screening Mammography Extend Past Age 70 (0 replies)
914. Drugs Cut Bone Loss of Hormone Therapy (0 replies)
915. male breast cancer remains below the radar. (1 replies)
916. Amgen Bone Drug Shows Promise (2 replies)
917. Male relatives carry risk from breast cancer genes: study (0 replies)
918. Most Doctors' Breast Exams Fail Test (3 replies)
919. Herceptin Helps Women with Multiple Chromosomes Containing HER2 Gene (0 replies)
920. Treatment With Zoledronic Acid Prevents Aromatase Inhibitor-Caused Bone Loss (0 replies)
921. Progesterone in Dairy Products Poses Risks (0 replies)
922. High Dose Fulvestrant reduces tumor growth (0 replies)
923. Genomics Helps Predict Best Treatment (1 replies)
924. Some Women Get Less Benefit from Tamoxifen (0 replies)
925. Zometa Offers Three Years of Bone Benefit (0 replies)
926. Long-term data show superiority of anastrazole over tamoxifen in early breast cancer (0 replies)
927. Change in annual recurrence rates over the last 10 years - NORA study (0 replies)
928. HER2 Homodimer and HER2 Total Protein Assays (0 replies)
929. Recurrence in Node-Positive Breast Cancer Treated With Tamoxifen (0 replies)
930. Pregnancy May Dampen Breast Cancer Survival (0 replies)
931. Only HER2 Breast Cancer benefits from Adrymycian (0 replies)
932. AI's in early breast cancer toxicity and adherence (0 replies)
933. Gene testing for b/c in men (0 replies)
934. Mechanism of action of herceptin killing of HER-2+ breast cancer cells under in vitro (0 replies)
935. The clinical significance of polysomy 17 in the HER2+ N9831 intergroup adjuvant trast (0 replies)
936. Impact of ERBB2 on prognosis and microarray data (0 replies)
937. Comparison of joint problems as reported by patients in a randomised adjuvant trial (0 replies)
938. Shorter Radiation Breast Cancer treatment (1 replies)
939. Stem Cells in Breast Cancer (0 replies)
940. HER2 Vaccine Show Promise in Preliminary Testing (1 replies)
941. New Website for Brain Metastases (0 replies)
942. promise in reducing side effects from anastrozole (0 replies)
943. Survival Benefit of Docetaxel Over Doxorubicin in Breast Cancer (0 replies)
944. Genetic Test predicts when chemo benefit to spread to lymph nodes (0 replies)
945. Naviscan's PEM Flex(TM) Scanner Shows Promise (0 replies)
946. A Call to scrap Anthracyclines in Breast Cancer (0 replies)
947. Triple Negative Breast Cancer (1 replies)
948. High Dose Chemo Doesn't Help Breast Cancer (0 replies)
949. SABCS to be renamed (0 replies)
950. Some With Breast Cancer Can Skip Chemo (8 replies)
951. Milk Products are a Source of Dietary Progesterone (0 replies)
952. Increased prevalance of retinal hemorrages among anastrozole users (0 replies)
953. The Effects of vaginal estrogens on plasma estradiol levels in women taking AI's (0 replies)
954. Her2 Recurrence Rates pre-Herceptin (9 replies)
955. Abstracts Available on Line (0 replies)
956. San Antonio Meeting 2007 (0 replies)
957. San Antonio Meeting 2007 (0 replies)
958. Her2 Posters Utilizing VeraTag Assays to be presented at SABCS (0 replies)
959. ASCO 2007 Highlights (5 replies)
960. More San Antonio Summaries (0 replies)
961. ***12/24/01 was the launch of...*** (0 replies)
962. one of the big topics at SABCS:epigenetics producing clinical results>80%responserate (0 replies)
963. from San Antonio--new way to evaluate lymph nodes 4 mets with intraoperative results! (0 replies)
964. High Breast Density Puts Women With DCIS at High Risk of Contralateral Invasive Breas (0 replies)
965. Chemo regimen found inferior (0 replies)
966. Less-toxic remedies gain in battle on breast cancer (2 replies)
967. Pill Fights Deadly Breast Cancer (0 replies)
968. Aromasin May Cut Breast Cancer Return (0 replies)
969. SABCS: Anthracycline May Be Superfluous in Breast Cancer Regimens (2 replies)
970. Ending Periods Helps Cancer Survival (0 replies)
971. Hsp90 Inhibitor, Tanespimycin (0 replies)
972. perspectives (0 replies)
973. Tests predict breast-cancer response (0 replies)
974. 2006 Komen Brinker Awards (0 replies)
975. Comparison, ACT + Herceptin, TC + Herceptin (8 replies)
976. Roche's Xeloda, Avastin in combination offer cancer patients clinical benefit (1 replies)
977. Breast cancer drop tied to hormones (0 replies)
978. Analysis: Breast-cancer vaccine advancing (0 replies)
979. Lapatinib Effective for Inflammatory Breast Cancer: Presented at SABCS (0 replies)
980. Arimidex Plus trastuzumab (Phase III TAnDEM study results) (0 replies)
981. Walter Reed Cancer Vaccine (1 replies)
982. Basics on San Antonio (0 replies)
983. Another Live Webcast from San Antonio Sunday December 17th (0 replies)
984. Circulating Tumor Cells (4 replies)
985. Sabcs (0 replies)
986. Live Webcast from The San Antonio Breast Cancer Symposium (0 replies)
987. This Forum (0 replies)

vBulletin® v3.8.7, Copyright ©2000-2025, vBulletin Solutions, Inc.